Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Arbutus Biopharma Corporation ABUS

Set alert

Price alert · ABUS

All alert types
4.00 USD -0.21 -4.99%

At close · Nov 2

3.96 -0.04 -1.00%

After hours · Nov 2, 5:40 PM ET

Bid
3.99 × 2
Ask
4.00 × 2
3.99 Day range 4.29
3.67 52-week range 5.22
YTD
-16.84%
1 year
-15.43%
Open
4.22
Prev close
4.21
Mkt cap
613.10M
Vol
2.65M
Avg vol
4.91M
EPS
0.75
P/E
5.33
Div yield
0.00%
More statistics
Low
3.99
High
4.29
Forward P/E
-30.67
Beta
0.62
Short ratio
5.03
Inst. own
72.71%
Dividend
0.00
Ex-div date
Earnings
Nov 16, 2026
50-d avg
4.79
200-d avg
4.52
1y target
5.46

YTD chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Mar 23, 2026Earnings: -0.01; estimate -0.03505; surprise 71.47%
  • May 13, 2026Earnings: 0.87; estimate -0.03; surprise 3000%
  • Aug 12, 2026Earnings: -0.03; estimate -0.02; surprise -50%
Signals (68)
NameDateAgo
MACD: Buy SignalOct 22, 20261 week ago
RSI: OversoldOct 12, 20263 weeks ago
RSI: OversoldOct 8, 20263 weeks ago
SMA: BearishOct 6, 20263 weeks ago
SMA: BullishOct 5, 20264 weeks ago
SMA: BearishOct 2, 20261 month ago
RSI: OversoldOct 2, 20261 month ago
SMA: BearishSep 29, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
MACD: Buy SignalAug 6, 20262 months ago
SMA: BullishAug 5, 20262 months ago
SMA: BullishAug 5, 20262 months ago
SMA: BearishJul 24, 20263 months ago
SMA: BullishJul 23, 20263 months ago
SMA: BearishJul 22, 20263 months ago
SMA: BearishJul 22, 20263 months ago
SMA: BullishJul 21, 20263 months ago
SMA: BullishJul 21, 20263 months ago
SMA: BearishJul 20, 20263 months ago
SMA: BearishJul 20, 20263 months ago

Newest 20 of 68.

Analyst view

Consensus: none

Price target (mean) 5.46
Ratings (0m) 1 1 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 1
  • 1 month ago 1
  • 2 months ago 2

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

ABUS analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.028-0.028 – -0.028-0.05601+50.0%1.39M+87.4%1
Next quarter-0.028-0.028 – -0.028-0.01372-104.1%1.39M-3.7%1
Current year1.031.03 – 1.03-0.23321+540.4%252.84M+1208.8%1
Next year-0.111-0.111 – -0.1111.03-110.8%5.69M-97.8%1

Upgrades and downgrades

The latest rating changes

ABUS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 14, 2025Chardan CapitalMaintainedBuyBuy
Aug 11, 2025Chardan CapitalMaintainedBuyBuy
Mar 28, 2025Chardan CapitalMaintainedBuyBuy
Jan 21, 2025HC Wainwright & Co.ReiteratedBuyBuy
Nov 20, 2024Chardan CapitalMaintainedBuyBuy
Nov 18, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 7, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 6, 2024Chardan CapitalMaintainedBuyBuy
Sep 5, 2024JefferiesMaintainedBuyBuy
Aug 2, 2024JMP SecuritiesMaintainedMarket OutperformMarket Outperform
Jun 7, 2024HC Wainwright & Co.ReiteratedBuyBuy
Jun 6, 2024HC Wainwright & Co.ReiteratedBuyBuy
Jun 5, 2024Chardan CapitalMaintainedBuyBuy
May 3, 2024Chardan CapitalReiteratedBuyBuy
Apr 4, 2024JMP SecuritiesReiteratedMarket OutperformMarket Outperform
Mar 1, 2024Chardan CapitalReiteratedBuyBuy
Mar 1, 2024HC Wainwright & Co.MaintainedBuyBuy
Sep 12, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 4, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 4, 2023Chardan CapitalReiteratedBuyBuy
Jul 11, 2023HC Wainwright & Co.ReiteratedBuyBuy
Jul 6, 2023JMP SecuritiesReiteratedMarket OutperformMarket Outperform
Jun 22, 2023HC Wainwright & Co.ReiteratedBuyBuy
Jun 22, 2023Chardan CapitalReiteratedBuyBuy
May 5, 2023HC Wainwright & Co.Reiterated—Buy
Apr 28, 2023HC Wainwright & Co.Reiterated—Buy
Apr 5, 2023HC Wainwright & Co.Reiterated—Buy
Mar 29, 2023JMP SecuritiesReiterated—Market Outperform
Mar 20, 2023HC Wainwright & Co.Reiterated—Buy
Mar 3, 2023Chardan CapitalReiterated—Buy